Sarah Boyce - Nov 1, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Former Director
Signature: /s/ Charles Berkman, Attorney-in-Fact
Stock symbol: LGND
Transactions as of: Nov 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 11/3/2022, 09:06 PM
Previous filing: Aug 26, 2022
Next filing: Nov 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Disposed to Issuer		-1K	-25.77%		2.89K	Nov 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LGND	Employee Stock Option (right to buy)	Disposed to Issuer		-4.34K	-100%		0	Nov 1, 2022	Common Stock	4.34K	$90.68	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sarah Boyce is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2	The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023.